DÜSSELDORF, Germany, Jan. 18, 2023 /PRNewswire/ -- Orthogen AG, a leader in molecular medicine, announces U.S. Food and Drug Administration (FDA) approval of an Investigational Device Exemption (IDE) ...
Orthogen AG received an investigational device exemption (IDE) from the U.S. FDA for its Orthogen technology device. This approval allows the company to start a pivotal trial on the device, used for ...
Orthogen's nanotechnology-based bone graft product, NanoGen, is a nanocrystalline calcium sulfate material provided in granular form, according to the company. Once implanted in the body, it undergoes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results